| Dr Larry Standing, DO | |
|
226 Blue Bell Rd, Cedar Falls, IA 50613-0000 | |
| (319) 575-5800 | |
| (319) 575-5855 |
| Full Name | Dr Larry Standing |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 33 Years |
| Location | 226 Blue Bell Rd, Cedar Falls, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922036276 | NPI | - | NPPES |
| 4092841 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2762 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Waterloo Home Health Care | Waterloo, IA | Home health agency |
| Care Initiatives Hospice - Cedar Falls | Cedar falls, IA | Hospice |
| Cedar Valley Hospice | Waterloo, IA | Hospice |
| Mercyone Waterloo Medical Center | Waterloo, IA | Hospital |
| Sartori Memorial Hospital, Inc | Cedar falls, IA | Hospital |
| Allen Hospital | Waterloo, IA | Hospital |
| Newaldaya Lifescapes | Cedar falls, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Covenant Medical Center Inc | 0244148732 | 211 |
News Archive
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
Women with a healthy body weight before and after diagnosis of breast cancer are more likely to survive the disease long term, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.
Lincor Solutions has secured an exclusive distribution agreement with Hills Health Solutions to deploy Lincor's next generation interactive patient care technology in Australian and New Zealand hospitals and aged care facilities for the first time.
Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.
› Verified 7 days ago
| Entity Name | Covenant Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548288160 PECOS PAC ID: 0244148732 Enrollment ID: O20031111000534 |
News Archive
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
Women with a healthy body weight before and after diagnosis of breast cancer are more likely to survive the disease long term, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.
Lincor Solutions has secured an exclusive distribution agreement with Hills Health Solutions to deploy Lincor's next generation interactive patient care technology in Australian and New Zealand hospitals and aged care facilities for the first time.
Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Larry Standing, DO 2101 Kimball Ave, Ll14, Waterloo, IA 50702-5063 Ph: (319) 272-1590 | Dr Larry Standing, DO 226 Blue Bell Rd, Cedar Falls, IA 50613-0000 Ph: (319) 575-5800 |
News Archive
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
Women with a healthy body weight before and after diagnosis of breast cancer are more likely to survive the disease long term, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
Due to their broad antitumor activity that inhibits the function of microtubules, taxanes are common chemotherapeutic agents utilized for the management of multiple cancer types from breast to prostate. Unfortunately, the frequency of their use is equally matched by the rates of expected and well known side effects.
Lincor Solutions has secured an exclusive distribution agreement with Hills Health Solutions to deploy Lincor's next generation interactive patient care technology in Australian and New Zealand hospitals and aged care facilities for the first time.
Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.
› Verified 7 days ago
Khushman Dodd, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5100 Prairie Pkwy Ste 301, Cedar Falls, IA 50613 Phone: 319-277-1990 Fax: 319-222-2999 | |
Dr. Jayasakthi Palaniappan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Bluebell Rd, Cedar Falls, IA 50613 Phone: 319-575-5800 | |
Ryan Neuhaus, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 5100 Prairie Pkwy Ste 205, Cedar Falls, IA 50613 Phone: 319-222-2711 | |
Dr. John Mark Zehr, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1227 W 27th St, Cedar Falls, IA 50614 Phone: 319-273-2009 Fax: 319-273-7030 | |
Dr. Kelly Jay Schmidt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5100 Prairie Pkwy Ste 101, Cedar Falls, IA 50613 Phone: 319-553-0828 Fax: 319-277-7548 | |
Susan L Woo, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2624 Orchard Dr, Cedar Falls, IA 50613 Phone: 319-277-1990 Fax: 319-277-0572 | |
Dr. Julie Renee Sandell, D.O.,F.P. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Bluebell Rd, Cedar Falls, IA 50613 Phone: 319-575-5800 Fax: 319-575-5855 |